Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.64 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9539594 | 0.90 | PARP10 (0.53) | TTRPARP10SRD5A2LPAR1LPAR5 | |
| SCHEMBL10703394 | 0.88 | PARP10 (0.51) | TTRAKR1C3PARP10SRD5A2LPAR1 | |
| SCHEMBL10487356 | 0.87 | PARP10 (0.50) | TTRPARP10SRD5A2LPAR1LPAR5 | |
| SCHEMBL28128705 | 0.87 | PARP10 (0.67) | TTRPARP10LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL3130872 | 0.86 | TTR (0.68) | TTRAKR1C3PARP10SRD5A2LPAR1 | |
| SCHEMBL8848427 | 0.84 | CES1 (0.49) | TTRPARP10LPAR1LPAR5LMNA | |
| SCHEMBL29174197 | 0.84 | TTR (0.54) | TTRPARP10LMNARAB9ASMN1; SMN2 | |
| SCHEMBL11462504 | 0.84 | TTR (0.81) | TTRAKR1C3PARP10SRD5A2RAB9A | |
| SCHEMBL10799090 | 0.83 | PARP10 (0.47) | TTRAKR1C3PARP10SRD5A2LPAR1 | |
| SCHEMBL11051862 | 0.83 | PARP10 (0.47) | TTRPARP10LPAR1LPAR5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116338026-A | Liquid chromatography tandem mass spectrometry detection method for detecting pesticides and metabolites thereof in protein-containing body fluid | 华南农业大学 | 2023-06-27 | — | — | CN | claimed |
| WO-2023005682-A1 | METHOD FOR ANALYZING TARGETED EXPOSURE GROUP OF ENVIRONMENTAL POLLUTANTS IN PLASMA, AND USE THEREOF | 暨南大学 | 2023-02-02 | — | — | WO | claimed |
| CN-111721856-B | Method for detecting pyrethroid pesticide metabolite in tea | 中国农业科学院茶叶研究所 | 2022-12-13 | — | — | CN | claimed |
| CN-114813992-A | Method for detecting phenols, esters and pesticide intermediates in urine | 上海交通大学医学院 | 2022-07-29 | — | — | CN | claimed |
| CN-113671068-A | Method for analyzing environmental pollutant targeting exposure component in blood plasma and application thereof | 暨南大学 | 2021-11-19 | — | — | CN | claimed |
| CN-111721856-A | Method for detecting pyrethroid pesticide metabolite in tea | 中国农业科学院茶叶研究所 | 2020-09-29 | — | — | CN | claimed |
| US-20140030741-A1 | In Vitro Method for Determining Presence of Type II Pyrethroids | GIVAUDAN S.A. (CH) | 2014-01-30 | — | — | US | claimed |
| EP-2642851-A1 | IN VITRO METHOD FOR DETERMINING PRESENCE OF TYPE II PYRETHROIDS | Givaudan SA (CH) | 2013-10-02 | — | — | EP | claimed |
| CN-103298337-A | In vitro method for determining presence of type II pyrethroids | GIVAUDAN SA | 2013-09-11 | — | — | CN | claimed |
| WO-2012069571-A1 | IN VITRO METHOD FOR DETERMINING PRESENCE OF TYPE II PYRETHROIDS | GIVAUDAN SA (CH) | 2012-05-31 | — | — | WO | claimed |
| EP-0017882-A1 | Process for the preparation of 3-phenoxy-4-fluoro-benzoic acid | BAYER AG (DE) | 1980-10-29 | — | — | EP | claimed |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-117310025-A | Method for screening key metabolites and pathways of ketosis based on double-platform metabolome | 宁夏大学 | 2023-12-29 | — | — | CN | disclosed |
| EP-0048375-A1 | Process for the preparation of 3-bromo-4-fluoro-benzoic acid | BAYER AG (DE) | 1982-03-31 | — | — | EP | disclosed |
| EP-0024516-A1 | 4-Fluoro-3-bromobenzoyl fluoride, process for its preparation and for the preparation of 4-fluoro-3-bromobenzoic acid therefrom | BAYER AG (DE) | 1981-03-11 | — | — | EP | disclosed |
| EP-0017882-A1 | Process for the preparation of 3-phenoxy-4-fluoro-benzoic acid | BAYER AG (DE) | 1980-10-29 | — | — | EP | disclosed |
| EP-0017882-A1 | Process for the preparation of 3-phenoxy-4-fluoro-benzoic acid | BAYER AG (DE) | 1980-10-29 | — | — | EP | disclosed |
| EP-0017882-A1 | Process for the preparation of 3-phenoxy-4-fluoro-benzoic acid | BAYER AG (DE) | 1980-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | TTR 193/4885AKR1C3 547/4885PARP10 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.